Treatment of mycophenolate-resistant immune-related organizing pneumonia with infliximab

Journal for ImmunoTherapy of Cancer

Volumn 6, Issue 1, 2018, Pages

  Ortega Sanchez, Guacimara ^a   Jahn, Kathleen ^a   Savic, Spasenija ^b   Zippelius, Alfred ^a   Läubli, Heinz ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Cancer immunotherapy; Immune checkpoint inhibitor; Immune related adverse event; Lung; Pneumonitis

Indexed keywords

CORTICOSTEROID; DABRAFENIB; FLUORODEOXYGLUCOSE F 18; INFLIXIMAB; MYCOPHENOLATE MOFETIL; PEMBROLIZUMAB; PREDNISONE; PROGRAMMED DEATH 1 RECEPTOR; TRAMETINIB; ANTINEOPLASTIC AGENT; CTLA4 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT; IPILIMUMAB; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID; PDCD1 PROTEIN, HUMAN; TNF PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

AGED; ARTICLE; BONE LESION; CASE REPORT; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSPNEA; HUMAN; HUMAN TISSUE; IMMUNOTHERAPY; LUNG LAVAGE; LUNG LESION; LUNG NODULE; MALE; METASTATIC MELANOMA; MULTIPLE CYCLE TREATMENT; MYCOPHENOLATE RESISTANT ORGANIZING PNEUMONIA; NEW YORK HEART ASSOCIATION CLASS; ORGANIZING PNEUMONIA; PALLIATIVE THERAPY; PANCREAS CANCER; PRIORITY JOURNAL; RETROPERITONEAL CANCER; SKIN DEFECT; DRUG RESISTANCE; MELANOMA; PNEUMONIA;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; CTLA-4 ANTIGEN; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLIXIMAB; IPILIMUMAB; MALE; MELANOMA; MYCOPHENOLIC ACID; PNEUMONIA; PROGRAMMED CELL DEATH 1 RECEPTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85052692791     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/s40425-018-0400-4     Document Type: Article

References (28)

1. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350-5.
2. Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321-30.
3. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27(4):450-61.
4. Haanen J, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv119-iv42.
5. Heinzerling L, Goldinger SM. A review of serious adverse effects under treatment with checkpoint inhibitors. Curr Opin Oncol. 2017;29(2):136-44.
6. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158-68.
7. Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol. 2016;27(4):559-74.
8. Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015;26(12):2375-91.
9. Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, et al. Overall survival with combined Nivolumab and Ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345-56.
10. Motzer RJ, Tannir NM, DF MD, Aren Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018;378(14):1277-90.
11. Possick JD. Pulmonary toxicities from checkpoint immunotherapy for malignancy. Clin Chest Med. 2017;38(2):223-32.
12. Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J, et al. Pneumonitis in patients treated with anti-programmed Death-1/programmed death ligand 1 therapy. J Clin Oncol. 2017;35(7):709-17.
13. Howell M, Lee R, Bowyer S, Fusi A, Lorigan P. Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer. Lung Cancer. 2015;88(2):117-23.
14. June CH, Warshauer JT, Bluestone JA. Is autoimmunity the Achilles' heel of cancer immunotherapy? Nat Med. 2017;23(5):540-7.
15. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443-54.
16. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018-28.
17. Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA, et al. Overall survival and long-term safety of Nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung Cancer. J Clin Oncol. 2015;33(18):2004-12.
18. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung Cancer. N Engl J Med. 2015;373(17):1627-39.
19. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung Cancer. N Engl J Med. 2015;373(2):123-35.
20. Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung Cancer. N Engl J Med. 2016;375(19):1823-33.
21. Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, et al. First-line Nivolumab in stage IV or recurrent non-small-cell lung Cancer. N Engl J Med. 2017;376(25):2415-26.
22. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23-34.
23. Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced Cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;2(12):1607-16.
24. Khunger M, Rakshit S, Pasupuleti V, Hernandez AV, Mazzone P, Stevenson J, et al. Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung Cancer: a systematic review and meta-analysis of trials. Chest. 2017;152(2):271-81.
25. Nishino M, Ramaiya NH, Awad MM, Sholl LM, Maattala JA, Taibi M, et al. PD-1 inhibitor-related pneumonitis in advanced Cancer patients: radiographic patterns and clinical course. Clin Cancer Res. 2016;22(24):6051-60.
26. Chen YL, Zhao J, Jia R, Wang HY, Zheng J, Bai CQ, et al. Immune-related pneumonitis caused by programmed death-1 inhibitor Pembrolizumab: a case report and literature review. Zhonghua Jie He He Hu Xi Za Zhi. 2017;40(10):736-43.
27. Lu CS, Liu JH. Pneumonitis in cancer patients receiving anti-PD-1 and radiotherapies: three case reports. Medicine (Baltimore). 2017;96(1):e5747.
28. Nishino M, Sholl LM, Hodi FS, Hatabu H, Ramaiya NH. Anti-PD-1-related pneumonitis during Cancer immunotherapy. N Engl J Med. 2015;373(3):288-90.